07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Osiris management update

Osiris Therapeutics Inc. (NASDAQ:OSIR), Columbia, Md.   Business: Cancer, Cardiovascular, Musculoskeletal   Hired: Theresa Dixon as general manager of market access and reimbursement, formerly VP of government affairs and health economics at Advanced BioHealing Inc....
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Organogenesis, Shire deal

Organogenesis purchased wound healing product Dermagraft human fibroblast-derived dermal substitute ( ABH001 ) from Shire. Shire will not receive an upfront payment but is eligible for up to $300 million in milestones based on annual...
02:17 , Jan 18, 2014 |  BC Extra  |  Company News

Organogenesis acquires Shire's Dermagraft

Regenerative medicine company Organogenesis Inc. (Canton, Mass.) purchased wound healing product Dermagraft from Shire plc (LSE:SHP; NASDAQ:SHPG). Shire will not receive an upfront payment but is eligible for up to $300 million in milestones through...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Dermagraft: Development discontinued

Shire disclosed in its 3Q13 earnings that it discontinued development of ABH001 to treat epidermolysis bullosa as part of a pipeline prioritization. The product was in an open-label, international Phase III trial. Shire said the...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

Dermagraft: Phase III started

Shire began an open-label, international Phase III trial to compare topical ABH001 applied every 4 weeks plus protocol-specified dressings vs. control wound care plus protocol-specified dressings for up to 24 weeks in about 20 patients...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Lotus Tissue Repair, Shire deal

Shire will acquire Lotus Tissue Repair for an undisclosed upfront payment, plus milestones. Shire will gain Lotus Tissue's lead product, a preclinical recombinant form of human collagen Type VII (rC7) in development as an IV...
01:52 , Nov 16, 2012 |  BC Extra  |  Company News

Jonas to head Shire's regenerative medicine business

Shire plc (LSE:SHP; NASDAQ:SHPG) named Jeff Jonas president of Shire's regenerative medicine business, which Shire gained through its acquisition of Advanced BioHealing Inc. last year. Jonas replaces Kevin Rakin, who was chairman and CEO of...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

Dermagraft regulatory update

Shire said Health Canada approved Dermagraft human fibroblast-derived dermal substitute to treat diabetic foot ulcers. The company plans to launch the product in Canada in 1Q13. Dermagraft is already marketed in the U.S. for the...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Shire neurology, dermatology news

Shire disclosed its 1Q12 earnings two legal investigations related to ADHD drugs Adderall XR amphetamine and Vyvanse lisdexamfetamine and to diabetic foot ulcer therapy Dermagraft . On April 5, it received a Civil Investigative Demand...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Company News

Pervasis, Shire deal

Shire will acquire Pervasis' vascular assets in a deal valued at up to $200 million, including an undisclosed upfront payment and milestones. The deal includes Vascugel , a biodegradable implant containing human endothelial cells in...